Monthly shot to help keep weight off after switching from semaglutide or tirzepatide
Treatments studied
Part of Hormones & metabolism clinical trials.
This study tests a new once-a-month medicine for people who have already been taking a weight-loss medication and want to keep the weight off. Participants will switch from their current medicine (semaglutide or tirzepatide) to the study drug.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You are currently taking semaglutide (like Wegovy or Ozempic) or tirzepatide (like Mounjaro or Zepbound) for weight management.
- You have not been diagnosed with any type of diabetes.
- You have no history of pancreatitis (inflammation of the pancreas).
- You have no personal or family history of a rare thyroid cancer called medullary thyroid carcinoma (MTC) or a genetic condition called multiple endocrine neoplasia type 2 (MEN-2).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a once-weekly injection (tirzepatide) versus a placebo to help people who are obese or overweight with related health conditions lose weight. You may qualify if you have tried to lose weight through diet before, but have not been successful.
This study tests a weekly injection called semaglutide to see how well it helps people with obesity lose weight, compared to a similar approved medicine, Wegovy. It may be an option if you have struggled to lose weight in the past.
This study tests a medication called semaglutide (a once-weekly injection) to help people with obesity lose weight. It is for adults who have already tried lifestyle changes without success.
This study tests a new medicine called zenagamtide for adults with overweight or obesity, with or without type 2 diabetes, who are currently taking semaglutide. The goal is to see how well people tolerate switching from semaglutide to the new treatment.
This study tests whether a low dose of semaglutide (a once-weekly injection) can help obese adults without diabetes lose weight. Semaglutide works by reducing appetite and helping your body use food differently.
This study tests a new once-monthly injection, berobenatide, to see if it is safe and helps adults with obesity lose weight. It is for people in Japan who have obesity and related health problems like high blood pressure, high cholesterol, or type 2 diabetes.
Hear when a new Obesity trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.